|

[177Lu]Lu-NeoB Clinical Trials

2 actively recruiting trials across 1 location

Also known as: lutetium neoB

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • Novartis Pharmaceuticals2

Indications

  • Breast Cancer2
  • Cancer2

Los Angeles, California2 trials

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

UCLA Medical Center

Phase 1/2
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

UCLA Jonsson Comp Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.